Evotec presents paradigm shift in biologics at Capital Markets Day
Evotec SE today presents at its Capital Markets Day an update on how the Company is taking meaningful steps to transform biologics manufacturing to enable global access.
View ArticleJust - Evotec Biologics' J.POD® wins CPhI Pharma Award 2022 for Manufacturing...
Evotec SE today announced that the Company’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. has been selected as a winner of a CPhI Pharma Award 2022. Just – Evotec Biologics entered the...
View ArticleEvotec completes acquisition of Central Glass Germany
Evotec SE announced today that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
View ArticleEvotec SE to announce results for the first nine months 2022 on 09 November 2022
Evotec SE will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022.
View ArticleEvotec SE reports results for the first nine months 2022 and provides...
Evotec SE today announced the financial results and corporate updates for the first nine months 2022. Group revenues increased by 19% (13% excluding fx-effects) to € 510.8 m (9M 2021: € 431.0 m),...
View ArticleEvotec's partner Exscientia receives first CTA approval for Phase I/II trial...
Evotec’s partner Exscientia plc today announced clinical trial application (“CTA”) approval of a Phase I/II trial of EXS-21546, an A2a receptor antagonist, co-invented and developed through a...
View ArticleEvotec substiantially reduces carbon emissions by joining renewable energy...
Evotec SE announced today that the Company will substantially reduce its carbon emissions by joining the renewable energy heating network Toulouse Energie Durable (“TED”).
View ArticleEVT801 pre-clinical data published in peer-reviewed cancer research journal
Evotec partner Kazia Therapeutics Limited, an oncology-focused drug development company, announced the publication of positive pre-clinical data for EVT801, a clinical-stage drug candidate currently in...
View ArticleEvotec achieves further progress in neuroscience collaboration with Bristol...
Evotec SE announced today that the Company has achieved further significant progress within its neuroscience collaboration with Bristol Myers Squibb. The collaboration expands the portfolio by two...
View ArticleEvotec-partner Sernova provides update on development of iPSC-derived cell...
Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced today that significant progress has been achieved in its collaboration with Evotec SE. This progress includes...
View ArticleEvotec announces agreement with Janssen to develop immune-based therapies
Evotec SE announced today that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of...
View ArticleEvotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
Evotec SE announced today that the Company's Supervisory Board has appointed Laetitia Rouxel as new Chief Financial Officer and member of the Management Board effective 01 April 2023. She will take...
View ArticleEvotec and Related Sciences expand integrated drug discovery and development...
Evotec SE announced today that the Company has extended and expanded its integrated multi-target drug discovery agreement with data-driven biotech creation firm, Related Sciences (“RS”), to continue to...
View ArticleEvotec receives € 150 m loan from European Investment Bank
Evotec SE and the European Investment Bank (“EIB”) announced today that the EIB has granted Evotec an unsecured loan facility of € 150 m to support the Company’s R&D activities, equity investments...
View ArticleCyprotex US expands to new facility in Framingham, MA
Evotec SE announced today that Cyprotex US, LLC, the US site of Cyprotex a wholly owned subsidiary of Evotec, has completed its relocation from Watertown, MA to a new state-of-the-art facility in...
View ArticleEvotec-partner Sernova to present at the 4th IPITA / HSCI / JDRF Summit
Sernova Corp., a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet...
View ArticleEvotec announces progress in strategic protein degradation partnership with...
Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline. Performance-based and programme-based...
View ArticleEvotec SE to announce preliminary financial results for fiscal year 2022 on...
Evotec SE will announce its preliminary financial results for 2022 on Tuesday, 28 March 2023.
View ArticleCDMO Leadership Awards 2023
Evotec announces that the Company has been selected as a winner of a 2023 CDMO Leadership Award across all the six core categories included in the award program including Capabilities, Compatibility,...
View ArticleEvotec receives US$ 6.6 m grant for drug discovery in tuberculosis
Evotec SE announced today that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the...
View Article